TriSalus Life Sciences, Inc. — Earnings

Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR

Next earnings (estimated): Wed, April 1, 2026 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31$13M↑+59.8%
2025-09-30$12M↑+57.4%$-11M↓-350.6%-77.9%
2025-06-30$11M↑+52.3%$-8M↓-91.3%-65.4%
2025-03-31$9M↑+42.0%$-10M↑+21.4%-79.9%
2024-12-31$8M↑+44.4%
2024-09-30$7M↑+41.5%$-2M↓-68.4%-118.9%
2024-06-30$7M↑+59.7%$-4M↑+69.0%-111.0%
2024-03-31$6M↑+116.4%$-13M↓-58.9%-180.8%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q4)

Revenue
$13M
↑+59.8% +$5M YoY
Net Income
$7M
↑+158.2% +$4M YoY

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 21 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+1.4pts
86.7%
Operating Margin↑+41.0pts
-77.9%
Net Margin↓-60.8pts
-93.5%

Go deeper